Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Core Insights - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases [3] - The company will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 [1] - Fulcrum's lead program is pociredir, aimed at increasing fetal hemoglobin expression for treating sickle cell disease [3] Company Overview - Fulcrum Therapeutics specializes in addressing high unmet medical needs through proprietary technology that targets gene expression [3] - The company is actively developing treatments for rare diseases, particularly sickle cell disease, which is a significant area of focus [3] Event Information - The fireside chat will be accessible via a webcast, with a replay available for at least 30 days post-presentation [2]